Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto (HETHICO)
Sponsor: Quovadis Associazione
Listed as NCT04393805, this observational or N/A phase trial focuses on COVID-19 and Hypercoagulability and remains completed. Sponsored by Quovadis Associazione, it has been updated 8 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Study Description(click to expand)The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.
Furthermore, the possible association between the observed clinical evolution and the type of antithrombotic prophylaxis performed (class of drug and dose intensity) will be assessed in a large cohort of patients hospitalized in the various participating hospitals in the Veneto region and observed with follow-up. in the short term, gathering information on:
Clinical outcomes, Survival, Concomitant pathologies, Adverse events of anticoagulant drugs, Interactions with other concomitant drugs, and Risk factors.
The collected data, suitably anonymized, will be used to produce scientific works, the standardization of care paths, and the planning of targeted training events.
The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.
Furthermore, the possible association between the observed clinical evolution and the type of antithrombotic prophylaxis performed (class of drug and dose intensity) will be assessed in a large cohort of patients hospitalized in the various participating hospitals in the Veneto region and observed with follow-up. in the short term, gathering information on:
Clinical outcomes, Survival, Concomitant pathologies, Adverse events of anticoagulant drugs, Interactions with other concomitant drugs, and Risk factors.
The collected data, suitably anonymized, will be used to produce scientific works, the standardization of care paths, and the planning of targeted training events.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed
-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2021 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Oct 2020 — Jan 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Oct 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Quovadis Associazione
- University of Padova
For direct contact, visit the study record on ClinicalTrials.gov .